Breaking News, Collaborations & Alliances

Vertex, BMS To Conduct Combo-HCV Studies

Will evaluate VX-135 and daclatasvir in hepatitis C

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Vertex Pharmaceuticals has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct Phase II studies of once-daily oral treatments containing Vertex’s hepatitis C virus (HCV) polymerase inhibitor VX-135, and BMS’ NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C. Vertex will conduct two Phase II studies of the combination, including an initial study in treatment-naïve people with genotype 1 HCV infection. Vertex plans to begin a subsequent study w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters